ENT2 Antibody

Introduction to ENT2 Antibody

ENT2 antibodies are immunological reagents designed to detect and quantify ENT2 protein expression. These antibodies enable researchers to investigate ENT2's role in nucleoside transport, which influences processes like DNA repair, cell cycle regulation, and cancer progression . ENT2 is distinguished by its broad substrate specificity (purines, pyrimidines, and nucleobases) and insensitivity to nitrobenzylthioinosine (NBMPR) .

Nucleoside Transport and Cellular Metabolism

ENT2 facilitates equilibrative diffusion of nucleosides, supporting nucleic acid synthesis and energy metabolism. Unlike concentrative transporters (CNTs), ENT2 operates independently of sodium gradients .

Cancer Progression

High ENT2 expression correlates with advanced cancer stages, particularly in tumors with high metabolic demands (e.g., glioblastoma, breast cancer) . ENT2 mediates uptake of nucleoside-derived chemotherapeutics, making it a potential biomarker for treatment response .

Blood-Brain Barrier (BBB) Penetration

ENT2 enables transport of anti-DNA autoantibodies (e.g., DX1) across the BBB, a mechanism exploited in brain tumor immunotherapy. Knockdown of ENT2 via siRNA reduces DX1 uptake by 64% (P < 0.01) in brain endothelial cells .

Mechanistic Insights

• ENT2-Dependent Antibody Uptake: DX1, an anti-DNA autoantibody, leverages ENT2 to penetrate brain endothelial cells and suppress orthotopic glioblastoma in murine models .

• Synthetic Lethality: ENT2-mediated transport of 3E10 (a lupus autoantibody) inhibits DNA repair in PTEN-deficient cancers, demonstrating therapeutic potential .

Key Studies

Future Directions

ENT2 antibodies are pivotal for advancing cancer therapeutics and understanding nucleoside transport dynamics. Ongoing research explores:

• Bispecific Antibodies: Combining ENT2-targeting agents with checkpoint inhibitors .

• Biomarker Development: Correlating ENT2 expression with chemotherapeutic efficacy .